Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Hope and Challenges for Personalized Medicine Highlighted
March 22, 2010
- Sato to Launch OTC Version of Troxipide
March 22, 2010
- Roche Suspends Development of Ocrelizumab Due to Adverse Reactions
March 22, 2010
- J-CLEAR Created for Objective Assessment of Data from Clinical Studies
March 22, 2010
- Gov't Should More Strongly Support Pharma Industry: Dr Teshirogi
March 22, 2010
- Merck to More Actively Tie Up with Others in Early Development Stage
March 22, 2010
- Eli Lilly Japan's Sales Up 19% in 2009
March 22, 2010
- Torii to Develop Sublingual Desensitization Therapy for Pollinosis
March 22, 2010
- Mediceo to Cut Costs Taking Advantage of ALCs
March 22, 2010
- Takara Bio Ties Up with Univ. of Pennsylvania for HIV Gene Therapy
March 22, 2010
- Morimoto Proposes Shared Manufacturing Site in Shanghai
March 22, 2010
- Pfizer Discontinues PIII Study of Figitumumab for Advanced NSCLC
March 22, 2010
- Will the Era of DI Pharmacists Arrive?
March 22, 2010
- VEGF Trap-Eye Improved Visual Acuity in Patients with DME: Bayer
March 22, 2010
- Kyowa Kirin, Solasia Sign License Agreement for Sancuso in Asia
March 15, 2010
- Eli Lilly, Merck, Pfizer to Jointly Create Cancer DB in Asia
March 15, 2010
- NanoCarrier to Obtain Process Patent on NC-4016 in the US
March 15, 2010
- SymBio Begins PII Trial of Bendamustine for Aggressive NHL
March 15, 2010
- Tsumura to Procure Raw Materials for Kampo Medicines in Laos
March 15, 2010
- JCPM to Provide e-Learning Programs for Clinical Trials
March 15, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…